Description
Viread (Tenofovir disoproxil fumarate) 300mg Online
Viread (Tenofovir disoproxil fumarate) is an antiretroviral medicine. It is used with other medicines to treat hepatitis B virus and HIV. Viread alafenamide combination is used to treat human immunodeficiency virus (HIV) infection. HIV is the virus that causes acquired immune deficiency syndrome (AIDS). Darunavir, cobicistat, emtricitabine, and Viread alafenamide is usually given to patients who have yet not received any medicine for HIV infection. Viread alafenamide combination will not cure or prevent HIV infection or AIDS. It helps keep HIV from reproducing and appears to slow down the destruction of the immune system. This may help delay problems that are usually related to AIDS or HIV disease from occurring. Darunavir, cobicistat, emtricitabine, and Viread alafenamide will not keep you from spreading HIV to other people. People who receive darunavir, cobicistat, emtricitabine, and Viread alafenamide may continue to have other problems usually related to AIDS or HIV disease.
HIV-1 Infection: VIREAD is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older. The following points should be considered when initiating therapy with VIREAD for the treatment of HIV-1 infection: VIREAD should not be used in combination with STRIBILD, TRUVADA, or other products containing Viread disoproxil fumarate.
Chronic Hepatitis B: VIREAD is indicated for the treatment of chronic hepatitis B in adults. The following points should be considered when initiating therapy with VIREAD for the treatment of HBV infection: The indication in adults is based on safety and efficacy data from treatment of subjects who were nucleoside-treatment-naïve and subjects who were treatment-experienced with documented resistance to lamivudine. Subjects were adults with HBeAg-positive and HBeAg-negative chronic hepatitis B with compensated liver disease. VIREAD was evaluated in a limited number of subjects with chronic hepatitis B and decompensated liver disease.
